1
|
Miranda-Riestra A, Cercós MG, Trueta C, Oikawa-Sala J, Argueta J, Constantino-Jonapa LA, Cruz-Garduño R, Benítez-King G, Estrada-Reyes R. Participation of Ca 2+-Calmodulin-Dependent Protein Kinase II in the Antidepressant-Like Effects of Melatonin. Mol Pharmacol 2024; 106:107-116. [PMID: 39079719 DOI: 10.1124/molpharm.124.000890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2024] [Accepted: 06/26/2024] [Indexed: 08/18/2024] Open
Abstract
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine secreted by the pineal gland during the dark phase of the photoperiod. Its main function is the synchronization of different body rhythms with the dark-light cycle. Research on melatonin has significantly advanced since its discovery and we now know that it has considerable significance in various physiological processes, including immunity, aging, and reproduction. Moreover, in recent years evidence of the pharmacological possibilities of melatonin has increased. Indoleamine, on the other hand, has antidepressant-like effects in rodents, which may be mediated by the activation of calcium-calmodulin-dependent kinase II (CaMKII) and are also related to the regulation of neuroplasticity processes, including neurogenesis, synaptic maintenance, and long-term potentiation. Remarkably, patients with major depression show decreased levels of circulating melatonin in plasma. This review presents evidence of the antidepressant-like effects of melatonin in preclinical models and the participation of CaMKII in these actions. CaMKII's role in cognition and memory processes, which are altered in depressive states, are part of the review, and the effects of melatonin in these processes are also reviewed. Furthermore, participation of CaMKII on structural and synaptic plasticity and the effects of melatonin are also described. Finally, the advantages of using melatonin in combination with other antidepressants such as ketamine for neuroplasticity are described. Evidence supports that CaMKII is activated by melatonin and downstream melatonin receptors and may be the common effector in the synergistic effects of melatonin with other antidepressants. SIGNIFICANCE STATEMENT: This review compiled evidence supporting that melatonin causes antidepressant-like effects in mice through calmodulin kinase II stimulation of downstream melatonin receptors as well as the participation of this enzyme in neuroplasticity, memory, and cognition. Finally, we describe evidence about the effectiveness of antidepressant-like effects of melatonin in combination with ketamine.
Collapse
Affiliation(s)
- Armida Miranda-Riestra
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Montserrat G Cercós
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Citlali Trueta
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Julián Oikawa-Sala
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Jesús Argueta
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Luis A Constantino-Jonapa
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Ricardo Cruz-Garduño
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Gloria Benítez-King
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| | - Rosa Estrada-Reyes
- Laboratorio de Neurofarmacología (A.M.-R., J.O.-S., J.A., L.A.C.-J., G.B.-K.), Departamento de Neurofisiología, Dirección de Investigaciones en Neurociencias (M.G.C., C.T., R.C.-G.), and Laboratorio de Fitofarmacología, Dirección de Investigaciones en Neurociencias (R.E.-R.), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico
| |
Collapse
|
3
|
Matrov D, Imbeault S, Kanarik M, Shkolnaya M, Schikorra P, Miljan E, Shimmo R, Harro J. Comprehensive mapping of cytochrome c oxidase activity in the rat brain after sub-chronic ketamine administration. Acta Histochem 2020; 122:151531. [PMID: 32131979 DOI: 10.1016/j.acthis.2020.151531] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2019] [Revised: 02/21/2020] [Accepted: 02/21/2020] [Indexed: 10/24/2022]
Abstract
Ketamine is a noncompetitive antagonist of glutamatergic N-methyl-d-aspartate receptors. Its acute effects on healthy volunteers and schizophrenia patients mimic some acute psychotic, but also cognitive and negative symptoms of schizophrenia, and subchronic treatment with ketamine has been used as an animal model of psychotic disorders. Glutamatergic neurotransmission is tightly coupled to oxidative metabolism in the brain. Quantitative histochemical mapping of cytochrome c oxidase (COX) activity, which reflect long-term energy metabolism, was carried out in rats that received a daily subanaesthetic dose (30 mg/kg) of ketamine for 10 days. In total, COX activity was measured in 190 brain regions to map out metabolic adaptations to the subchronic administration of ketamine. Ketamine treatment was associated with elevated COX activity in nine brain sub-regions in sensory thalamus, basal ganglia, cortical areas, hippocampus and superior colliculi. Changes in pairwise correlations between brain regions were studied with differential correlation analysis. Ketamine treatment was associated with the reduction of positive association between brain regions in 66 % of the significant comparisons. Different layers of the superior colliculi showed the strongest effects. Changes in other visual and auditory brain centres were also of note. The locus coeruleus showed opposite pattern of increased coupling to mainly limbic brain regions in ketamine-treated rats. Our study replicated commonly observed activating effects of ketamine in the hippocampus, cingulate cortex, and basal ganglia. The current study is the first to extensively map the oxidative metabolism in the CNS in the ketamine model of schizophrenia. It shows that ketamine treatment leads to the re-organization of activity in sensory and memory-related brain circuits.
Collapse
Affiliation(s)
- Denis Matrov
- Department of Neuroscience, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Division of Neuropsychopharmacology, Department of Psychology, University of Tartu, Tartu, Estonia
| | - Sophie Imbeault
- Tallinn University Centre of Excellence in Neural and Behavioural Sciences, School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia
| | - Margus Kanarik
- Division of Neuropsychopharmacology, Department of Psychology, University of Tartu, Tartu, Estonia
| | - Marianna Shkolnaya
- Tallinn University Centre of Excellence in Neural and Behavioural Sciences, School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia
| | - Patricia Schikorra
- Tallinn University Centre of Excellence in Neural and Behavioural Sciences, School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia
| | - Ergo Miljan
- Tallinn University Centre of Excellence in Neural and Behavioural Sciences, School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia
| | - Ruth Shimmo
- Tallinn University Centre of Excellence in Neural and Behavioural Sciences, School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia
| | - Jaanus Harro
- Tallinn University Centre of Excellence in Neural and Behavioural Sciences, School of Natural Sciences and Health, Tallinn University, Tallinn, Estonia; Division of Neuropsychopharmacology, Department of Psychology, University of Tartu, Tartu, Estonia.
| |
Collapse
|
6
|
Rampino A, Taurisano P, Fanelli G, Attrotto M, Torretta S, Antonucci LA, Miccolis G, Pergola G, Ursini G, Maddalena G, Romano R, Masellis R, Di Carlo P, Pignataro P, Blasi G, Bertolino A. A Polygenic Risk Score of glutamatergic SNPs associated with schizophrenia predicts attentional behavior and related brain activity in healthy humans. Eur Neuropsychopharmacol 2017; 27:928-939. [PMID: 28651857 DOI: 10.1016/j.euroneuro.2017.06.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 04/13/2017] [Accepted: 06/10/2017] [Indexed: 11/17/2022]
Abstract
Multiple genetic variations impact on risk for schizophrenia. Recent analyses by the Psychiatric Genomics Consortium (PGC2) identified 128 SNPs genome-wide associated with the disorder. Furthermore, attention and working memory deficits are core features of schizophrenia, are heritable and have been associated with variation in glutamatergic neurotransmission. Based on this evidence, in a sample of healthy volunteers, we used SNPs associated with schizophrenia in PGC2 to construct a Polygenic-Risk-Score (PRS) reflecting the cumulative risk for schizophrenia, along with a Polygenic-Risk-Score including only SNPs related to genes implicated in glutamatergic signaling (Glu-PRS). We performed Factor Analysis for dimension reduction of indices of cognitive performance. Furthermore, both PRS and Glu-PRS were used as predictors of cognitive functioning in the domains of Attention, Speed of Processing and Working Memory. The association of the Glu-PRS on brain activity during the Variable Attention Control (VAC) task was also explored. Finally, in a second independent sample of healthy volunteers we sought to confirm the association between the Glu-PRS and both performance in the domain of Attention and brain activity during the VAC.We found that performance in Speed of Processing and Working Memory was not associated with any of the Polygenic-Risk-Scores. The Glu-PRS, but not the PRS was associated with Attention and brain activity during the VAC. The specific effects of Glu-PRS on Attention and brain activity during the VAC were also confirmed in the replication sample.Our results suggest a pathway specificity in the relationship between genetic risk for schizophrenia, the associated cognitive dysfunction and related brain processing.
Collapse
Affiliation(s)
- Antonio Rampino
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Paolo Taurisano
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Giuseppe Fanelli
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Mariateresa Attrotto
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Silvia Torretta
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Linda Antonella Antonucci
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Grazia Miccolis
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Giulio Pergola
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Gianluca Ursini
- Lieber Institute for Brain Development, Johns Hopkins University Medical Campus, 21205 Baltimore, MD, USA
| | - Giancarlo Maddalena
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Raffaella Romano
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Rita Masellis
- Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Pasquale Di Carlo
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Patrizia Pignataro
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Giuseppe Blasi
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
| | - Alessandro Bertolino
- Department of Basic Medical Science, Neuroscience and Sense Organs - University of Bari "Aldo Moro", Piazza Giulio Cesare 11, 70124 Bari, Italy; Psychiatry Unit - Bari University Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy.
| |
Collapse
|
7
|
Pehrson AL, Hillhouse TM, Haddjeri N, Rovera R, Porter JH, Mørk A, Smagin G, Song D, Budac D, Cajina M, Sanchez C. Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. J Pharmacol Exp Ther 2016; 358:472-82. [PMID: 27402279 PMCID: PMC4998672 DOI: 10.1124/jpet.116.233924] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Accepted: 07/08/2016] [Indexed: 12/13/2022] Open
Abstract
Major depressive disorder (MDD) is a common psychiatric disorder that often features impairments in cognitive function, and these cognitive symptoms can be important determinants of functional ability. Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in patients with MDD, including attention, processing speed, executive function, and memory. However, the cause of these effects is unclear, and there are several competing theories on the underlying mechanism, notably including regionally-selective downstream enhancement of glutamate neurotransmission and increased acetylcholine (ACh) neurotransmission. The current work sought to evaluate the ACh hypothesis by examining vortioxetine’s ability to reverse scopolamine-induced impairments in rodent tests of memory and attention. Additionally, vortioxetine’s effects on hippocampal extracellular ACh levels were examined alongside studies of vortioxetine’s pharmacokinetic profile. We found that acute vortioxetine reversed scopolamine-induced impairments in social and object recognition memory, but did not alter scopolamine-induced impairments in attention. Acute vortioxetine also induced a modest and short-lived increase in hippocampal ACh levels. However, this short-term effect is at variance with vortioxetine’s moderately long brain half life (5.1 hours). Interestingly, subchronic vortioxetine treatment failed to reverse scopolamine-induced social recognition memory deficits and had no effects on basal hippocampal ACh levels. These data suggest that vortioxetine has some effects on memory that could be mediated through cholinergic neurotransmission, however these effects are modest and only seen under acute dosing conditions. These limitations may argue against cholinergic mechanisms being the primary mediator of vortioxetine′s cognitive effects, which are observed under chronic dosing conditions in patients with MDD.
Collapse
Affiliation(s)
- Alan L Pehrson
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Todd M Hillhouse
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Nasser Haddjeri
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Renaud Rovera
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Joseph H Porter
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Arne Mørk
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Gennady Smagin
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Dekun Song
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - David Budac
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Manuel Cajina
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| | - Connie Sanchez
- Lundbeck Research USA, Paramus, New Jersey (A.L.P., G.S., D.S., D.B., M.C., C.S.); Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (C.S.); Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (T.M.H.); Psychology Department, Virginia Commonwealth University, Richmond, Virginia (T.M.H., J.H.P.); Univ Lyon, Université Claude Bernard Lyon 1, Inserm, Stem Cell and Brain Research Institute U1208, 69500 Bron, France (R.R., N.H.); and H. Lundbeck A/S, Copenhagen-Valby, Denmark (A.M.)
| |
Collapse
|